Combination immunotherapy for advanced melanoma gets early approval from NICE
The immunotherapy combination nivolumab/ipilimumab has been recommended for patients with advanced malignant melanoma, according to draft guidance from the National Institute for Health and Care Excellence (NICE).
The approval means that patients in England and Wales will be the first in…